Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

Trial status:Study Complete
Study Identifier:
BNT162-03
ClinicalTrials.gov Identifier:
NCT04523571
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Study Complete

Results available

Study Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)

Trial details

Medical Condition
  • COVID-19
    • Study Drug
  • Biological: BNT162b1
    • Phase
    Phase 1
    Sex
    Female & Male
    Age
    18 - 85 Years
    Estimated Trial Date
    Jul 2020 - Sep 2020

    Protocol summary

    This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.

    Trial locations

    Location
    Status
    Location
    Jiangsu Provincial Center for Disease Control and Prevention
    Taizhou, Jiangsu, China, 210009
    Status